The increased level of CD8+ T cells leads to a longer survival time (Wang et al., 2020), implying that infiltration of immune cells affects the prognosis of BLCA and may help develop the method to evaluate the immunotherapy response. The gene discussed is CD8A; the disease is bladder transitional cell carcinoma.